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Background: HIV infection is a known risk factor for cancer but little is known about HIV testing patterns and the
burden of HIV infection in cancer patients. We did a cross-sectional analysis to identify predictors of prior HIV testing
and to quantify the burden of HIV in black cancer patients in Johannesburg, South Africa.
Methods: The Johannesburg Cancer Case–control Study (JCCCS) recruits newly-diagnosed black cancer patients
attending public referral hospitals for oncology and radiation therapy in Johannesburg . All adult cancer patients
enrolled into the JCCCS from November 2004 to December 2009 and interviewed on previous HIV testing were
included in the analysis. Patients were independently tested for HIV-1 using a single ELISA test . The prevalence of
prior HIV testing, of HIV infection and of undiagnosed HIV infection was calculated. Multivariate logistic regression
models were fitted to identify factors associated with prior HIV testing.
Results: A total of 5436 cancer patients were tested for HIV of whom 1833[33.7% (95% CI=32.5-35.0)] were
HIV-positive. Three-quarters of patients (4092 patients) had ever been tested for HIV. The total prevalence of
undiagnosed HIV infection was 11.5% (10.7-12.4) with 34% (32.0–36.3) of the 1833 patients who tested HIV-positive
unaware of their infection. Men >49 years [OR 0.49(0.39–0.63)] and those residing in rural areas [OR 0.61(0.39–0.97)]
were less likely to have been previously tested for HIV. Men with at least a secondary education [OR 1.79(1.11–2.90)]
and those interviewed in recent years [OR 4.13(2.62 – 6.52)] were likely to have prior testing. Women >49 years
[OR 0.33(0.27–0.41)] were less likely to have been previously tested for HIV. In women, having children <5 years
[OR 2.59(2.04–3.29)], hormonal contraceptive use [OR 1.33(1.09–1.62)], having at least a secondary education
[OR:2.08(1.45–2.97)] and recent year of interview [OR 6.04(4.45–8.2)] were independently associated with previous HIV
testing.
Conclusions: In a study of newly diagnosed black cancer patients in Johannesburg, over a third of HIV-positive patients
were unaware of their HIV status. In South Africa black cancer patients should be targeted for opt-out HIV testing.
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HIV-1 infection was classified as a human carcinogen by
the International Agency for Research on Cancer (IARC)
in 1996 [1]. South Africa has the largest HIV burden
worldwide with an estimated 6.4 million people living with
HIV in mid-2012 [2]. Black Africans are disproportionately* Correspondence: mazvita.sengayi@nhls.ac.za
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groups. According to the South African 2012 HIV preva-
lence survey, prevalence in the reproductive age group
(15–49 years) was 22.7%, 0.6%, 4.6% and 1.0% in blacks,
whites, coloureds (mixed race) and Indians/Asians respect-
ively [2]. In order to understand the burden and spectrum
of HIV-related cancers, it is essential to identify people
with HIV and cancer co-morbidity. Strategies to identify
patients with both HIV infection and cancer include
screening for cancers at HIV clinics [3] and testing cancer
patients for HIV [4,5].l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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guidelines recommend provider-initiated HIV testing
and counselling (PITC) for all patients attending health-
care facilities [6]. PITC is defined as “HIV testing and
counselling that is initiated and offered by health-care
providers to all clients attending health-care facilities as
a standard component of care” [6]. The World Health
Organization recommends an ‘opt-out’ approach to
PITC in generalised HIV epidemics (i.e. where antenatal
HIV prevalence exceeds 1%), which not only obliges
health care workers to offer HIV testing to every patient,
but also incorporates the informed right of the patient
to decline the recommendation of an HIV test [7]. In
this paper, PITC and opt-out HIV testing will be used
synonymously.
PITC has been shown to increase HIV testing almost
three-fold in primary care clinics in Gauteng province,
South Africa, compared to referral to on-site voluntary
counselling and testing services [8]. Challenges to wide-
spread opt-out HIV testing include overburdening a
strained healthcare system, ensuring confidentiality in
shared consulting rooms, on-going staff training and
preventing test kit stock-outs [8]. Therefore there is still
a role for targeted PITC among high risk groups, including
in antenatal and post-natal clinics, tuberculosis treatment
facilities, family planning clinics, sexually transmitted in-
fections clinics and post-exposure prophylaxis centres [6].
Indeed, a recent systematic review of studies in antenatal
care concluded that the adoption of PITC can greatly in-
crease testing uptake [9].
HIV testing patterns in the general South African
population have been studied: a representative survey in
2005 found that being female, employed, aged 25–34
years, having a higher education and residing in an
urban area were all associated with greater knowledge of
HIV status [10]. Women have consistently been found to
be more likely to know their HIV status than men
[2,10-15], even after accounting for pregnancy-related
HIV testing [11]. The youth [14], older women [15] and
older men [11,12] are less likely to be tested; the ma-
jority of older men who test for HIV generally do so
when there is a medical indication [11]. Little is
known about HIV testing patterns and the burden of
HIV infection in cancer patients [4]. The aim of this
study was to identify factors associated with HIV test-
ing and to quantify the burden of HIV in newly diag-
nosed black cancer patients in Johannesburg, Gauteng
province, South Africa.
Methods
Ethics statement
The study was approved by the University of the
Witwatersrand Human Research Ethics Committee
(Medical).Study setting and design
Since 1995, the Johannesburg Cancer Case–control Study
(JCCCS) has recruited newly diagnosed self-defined
black cancer patients attending public referral hospitals
(Chris Hani Baragwanath, Hillbrow and Charlotte Maxeke
Johannesburg Academic Hospital) for oncology and radi-
ation therapy in the greater Johannesburg area [16]. To
date, over 20 000 black cancer patients have been inter-
viewed, of whom the majority (over 90%) have donated
blood specimens for evaluation of infectious and gen-
etic risk factors for cancer and their interactions with
socio-demographic and environmental factors col-
lected via questionnaire. At the time of the current
analysis, the JCCCS patient recruitment was confined
to only Charlotte Maxeke Johannesburg Academic Hos-
pital (CMJAH) (formerly Johannesburg General Hospital).Eligibility criteria
All patients with confirmed cancer, aged ≥ 18 years, who
were enrolled into the JCCCS at CMJAH from November
2004 to December 2009 and who were interviewed on
previous HIV testing, were included in this study.Procedures and definitions
Trained nurse counsellors used a standard questionnaire
to interview cancer patients in their preferred language
(usually Zulu or Sotho). All patients gave written or wit-
nessed verbal informed consent prior to being inter-
viewed and having blood drawn. Patients were asked
questions on place of birth, rural or urban residence,
schooling, reproductive history, use of hormonal contra-
ception, number of lifetime sexual partners, and alcohol
and tobacco use. From November 2004, in addition to
the standard questionnaire, all patients aged 55 or less
were asked about previous HIV testing. After November
2006, all recruited patients were interviewed on prior
HIV testing. Patients were asked the following questions
to explore their HIV testing patterns: Have you ever
been tested for HIV? Were you tested: before this illness/
at time of current illness only? Were you given the test
results? Are you willing to disclose your status? If yes, are
you HIV positive or negative?
Nurse counsellors took blood samples from consent-
ing patients at the time of interview, before patients had
received any cancer treatment. Blood samples were col-
lected in 10 ml red-top plain vacutainers. Serum separ-
ation was done by standard centrifugation, and serum
specimens were frozen at −20 to −30°C before batching
for HIV testing. Specimens were tested for HIV-1 using
a single Vironostika (HIV Uniform II plus O) micro
enzyme-linked immunosorbent assay (ELISA) test. Speci-
mens with inconclusive ELISA tests were classified as HIV
negative. All tests were done at the Serology Laboratory,
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nicable Diseases, Johannesburg.
Prior HIV testing was defined as self-reported history
of HIV testing before the current cancer illness. Aware-
ness of HIV status was defined as self-reported HIV
status consistent with the result of the HIV-1 ELISA test.
Cancers were classified according to the International
Classification of Diseases for Oncology Third Edition
(ICD-O-3) [17]. We classified cervical cancer (ICD-O
topography code C53), Kaposi sarcoma (ICD-O morph-
ology code M91403) and non-Hodgkin lymphoma (ICD-
O topography codes C82-83 or ICD-O morphology code
M9590 – 9595, M9670 – 9717 and M9820 - 9837) as
AIDS-defining cancers [18]. The majority (98.4%) of pa-
tients included in the analysis had verification of cancer
diagnosis by histology, haematology or cytology. Coding
of cancers was done by an experienced coder working
for the JCCCS and quality controlled by one of the
authors (MIU) who has extensive coding expertise; assist-
ance from oncologists, histopathologists and/or cytologists
was sought where needed.
Statistical analyses
We used means and proportions to describe the charac-
teristics of newly diagnosed cancer patients. We deter-
mined the ten most frequent cancers in men and in
women by HIV status and calculated the prevalence of
prior HIV testing, of HIV infection and of undiagnosed
HIV, with exact binomial 95% confidence intervals (CI).
We compared age-specific HIV prevalence in male and
female black cancer patients with HIV prevalence in
black men and women in the South African general
population, as reported in the 2008 national HIV preva-
lence survey [19]. We also calculated prevalence of HIV
and undiagnosed HIV by cancer type (see Additional file 1:
Table S6).
We fitted logistic regression models to identify factors
associated with prior HIV testing in black cancer patients.
Separate models were calculated for men and women.
The following variables were entered into the models: age
(≤49 years, >49 years), place of residence (rural vs. urban),
marital status (married, single, widowed, divorced), year of
interview, highest level of education achieved (none, pri-
mary and secondary/tertiary), alcohol use (non-drinkers,
moderate drinkers and heavy/binge drinkers), smoking
(non-smokers, ex-smokers, current light smokers and
current heavy smokers), lifetime number of sexual part-
ners (0–1, 2–5 and 6 or more), having children under the
age of five, cancer type (AIDS defining or other cancers),
hormonal contraceptive use (ever, never) and interviewer.
We had three nurse interviewers: interviewer 1, the most
senior interviewer, was with the study during the entire
period; interviewer 3 replaced interviewer 2 in September
2009. We classified alcohol use as follows: non-drinkers(<1 drink per week), moderate drinkers (1–7 drinks/week
for women, 1–14 drinks/week for men) and heavy/binge
drinkers (8 or more drinks/week or 4 or more drinks in a
single occasion for women, 15 or more drinks/week or 5
or more drinks in a single occasion for men) [20]. We
considered that some patients may have quit smoking due
to their illness; hence those who stopped smoking more
than 5 years prior to the date of interview were classified
as ex-smokers while those who smoked within 5 years of
the date of interview were classified as current smokers.
Current smokers were further classified into ‘light’ (1 –
14 g/day) and ‘heavy’ (15 g/day or more) current smokers,
assuming weights of 1 g per cigarette or hand rolled
cigarette or pipe [21].
We added variables to multivariate models sequen-
tially, starting with variables with the smallest p value in
univariate analysis. Likelihood ratio tests were performed
to determine which variables were kept in the models.
The final model for men was adjusted for age, place of
residence, highest level of education achieved, year of
interview and interviewer. The final model for women
was adjusted for age, highest level of education achieved,
year of interview, having children under the age of five,
hormonal contraceptive use and interviewer. Stata software
(version 13, Stata Corporation, College Station, Texas,
USA) was used for all analyses.
Results
Characteristics of cancer patients
Out of the 7012 eligible patients who were approached,
270 did not participate, 1300 were not interviewed on
HIV testing and 69 did not have HIV screening test
results (Figure 1). Reasons for non-participation were:
too sick/in pain 105 (39%), unable to communicate 56
(21%), refused 44 (16%), left before interview 33 (12%),
impaired cognitive function 28 (10%) and other 4 (2%).
The remaining study sample had 5436 patients with HIV
test results. Two thirds of patients were female and 54%
patients were 49 years old or younger (Table 1). The ma-
jority (89%) were urban dwellers and 58% were married
or lived with their partner. Forty percent of patients had
completed primary education or less. Fifteen percent
were heavy/binge alcohol drinkers and 28% were current
smokers. A quarter of all patients had had more than
five sexual partners in their lifetime. Only 13% had chil-
dren under the age of five. The majority of women
(63%) had previously used hormonal contraceptives.
Missing data were ≤2% for all variables, except for the
variable “having children under 5 years”, where 9.3% of
data were missing.
Cancers in men and women by HIV status
The five most common cancers in HIV-positive men were
Kaposi sarcoma (KS), non-Hodgkin lymphoma (NHL),
Figure 1 Flowchart of cancer patient recruitment (2004 – 2009).
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75% of all cancers (Table 2). In HIV-negative men, the
top five cancers were oro-pharyngeal, lung, oesophageal,
naso-laryngeal and stomach cancers, totalling 54% of
all cancers. For HIV-positive women, the five most
common cancers were cervical, breast, KS, NHL and
oro-pharyngeal cancer, totalling 84% of all cancers. In
HIV-negative women, the top five cancers were breast,
cervical, oesophageal, ovarian and uterine cancer, totalling
77% of all cancers.
HIV testing and prevalence in cancer patients
Among patients with available results, 1833 had a posi-
tive ELISA test, for a prevalence of HIV infection of
33.7% (95% CI 32.5-35.0). Out of the 1833 cancer pa-
tients with a positive HIV-1 test, 626 [34% (95% CI
32.0 – 36.3)] were unaware of their positive HIV sta-
tus. The overall prevalence of previously undiagnosed
HIV among all black cancer patients was 11.5% (95% CI
10.7-12.4): 626 patients out of 5436 patients with HIV test
results. Among the 3603 patients who tested HIV-1 nega-
tive, 1588 (44%) were unaware of their HIV status.
Figure 2 and Figure 3 compare the age-specific HIV
prevalence in black men and women with cancer to
black men and women in the general South Africanpopulation [19]. In men with KS or NHL age-specific
HIV prevalence was high ranging from 96.3% to 100%
for KS and 33.3% to 100% for NHL, in the age groups 20
to 60 years. In men with other cancers HIV prevalence
was generally slightly higher in black cancer patients
than in the black male population. HIV prevalence in
black men with other cancers rose with age, peaking in
the 35–39 years age group and then declining to below
10% in men 60 years or older. In women the pattern was
similar to that observed in men for KS, NHL and for
other cancers. The pattern differed for cervical cancer:
HIV prevalence was 100% in women aged 20–24 years
and steadily declined with increasing age to 10% in
women aged 60 or older (Figure 3).
Factors associated with prior HIV testing
A total of 4092 (75%) out of 5436 patients had ever been
tested for HIV; of those, 1303 (32%) had been tested be-
fore their current cancer illness. The remaining 2789
(68%) had been tested for HIV at the time of their cancer
illness or diagnosis. The median time elapsed since the
last HIV test at time of interview was 1.9 months (IQR
1.0 – 5.6). Only 19 (<1%) out of the 4092, who had ever
been tested, were unwilling to disclose the results of
their previous HIV test. Factors independently associated
Table 1 Characteristics of newly diagnosed black South
African cancer patients (2004 – 2009)
Characteristics N %
Age
≤49 years 2954 54.3
>49 years 2482 45.7
Mean (Standard deviation) 47.8 (12.2)
Place of residence
Urban 4840 89.0
Rural 591 10.9
Missing data 5 0.1
Gender
Male 1793 33.0
Female 3643 67.0
Marital status
Married/Living together 3147 57.9
Single/Never married 680 12.5
Widowed 737 13.6
Separated/Divorced 863 15.9
Missing data 9 0.2
HIV Screening test result
Negative 3603 66.3
Positive 1833 33.7
Level of education
None 549 10.1
Primary 1641 30.2
Secondary/Tertiary 3238 59.6
Missing data 8 0.2
Alcohol use
Non-drinkers 3253 59.8
Moderate drinkers 1342 24.7
Heavy/Binge drinkers 841 15.5
Smoking
Non-smokers 3436 63.2
Ex-smokers 457 8.4
Current smokers (1 – 14 g/day) 1099 20.2
Current smokers (15+ g/day) 444 8.2
Lifetime number of sexual partners
0-1 585 10.8
2-5 3401 62.6
6+ 1343 24.7
Missing data 107 2.0
Having children under 5 years
No 4233 77.9
Yes 700 12.9
Missing data 503 9.3
Table 1 Characteristics of newly diagnosed black South
African cancer patients (2004 – 2009) (Continued)
Cancer type
AIDS-defining 1923 35.4
Other cancers 3513 64.6
Hormonal contraceptive use (Women only)
Never 1329 36.5
Ever 2299 63.1
Missing data 15 0.4
Interviewer
Interviewer 1 3161 58.2
Interviewer 2 2074 38.1
Interviewer 3 201 3.7
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urban residence, higher level of education and more re-
cent year of interview (Table 3). For example, men with
secondary/tertiary education had a 1.79 times greater
odds of a prior HIV test than men with no education.
Similarly, in women, younger age, higher level of educa-
tion and more recent year of interview were associated
with prior testing. In addition, having children under the
age of five and hormonal contraceptive use were inde-
pendently associated with prior HIV testing (Table 4).
Discussion
The prevalence of HIV infection in black cancer pa-
tients diagnosed in a large tertiary academic hospital
in Johannesburg, South Africa was 34%, demonstrating a
higher HIV prevalence in black cancer patients than in
the general black population. While three-quarters of all
patients had ever been tested for HIV, about a third of the
infected patients were unaware of their HIV infection.
Overall more than 10% of all newly diagnosed black can-
cer patients had a previously unknown HIV infection. The
HIV prevalence in this population was substantially higher
than the national South African adult HIV prevalence of
18% [19] but comparable with other high risk groups. For
example, the National Antenatal Sentinel HIV and Syphilis
Prevalence survey showed that 29% of pregnant women
were HIV positive in 2009 [22]. HIV prevalence in cancer
patients is expected to be high since HIV is a well-
established risk factor for AIDS-defining cancers, but the
prevalence was also higher in patients with cancers that
are not classified as AIDS-defining. Overall HIV preva-
lence in cancer patients in a previous JCCCS publication
covering the period March 1995 – June 2004, was found
to be 10% [16]. The current analysis, covering the period
November 2004 - December 2009 found a much higher
prevalence of 34%. The difference in the HIV sero-
positivity reflects the different stages of the South African
HIV epidemic in the two time periods. The much lower
Table 2 Ten most frequent cancers in black South African men and women by HIV status (2004 – 2009)
HIV positive men (n = 596) HIV negative men (n = 1197)
Kaposi sarcoma 260 (43.6) Lip, oral cavity and pharynx 216 (18.1)
NHL 94 (15.8) Lung 167 (14.0)
Diffuse large B cell lymphoma 54 (9.1)
Burkitt’s lymphoma 6 (1.0)
Other NHL 34 (5.7)
Lip, oral cavity and pharynx 38 (6.4) Oesophagus 125 (10.4)
Lung 34 (5.7) Nasal cavity and larynx 82 (6.9)
Nasal cavity and larynx 21 (3.5) Stomach 54 (4.5)
Oesophagus 19 (3.2) Colon 45 (3.8)
Hodgkin Lymphoma 15 (2.5) Anorectal 45 (3.8)
Liver 11 (1.9) Liver 45 (3.8)
Stomach 9 (1.5) Pancreas 39 (3.3)
Skin (non-melanoma, non-SCC*) 7 (1.2) Prostate 39 (3.3)
HIV positive women (n = 1237) HIV negative women (n = 2406)
Cervix 448 (36.2) Breast 874 (36.3)
Breast 241 (19.5) Cervix 718 (29.8)
Kaposi sarcoma 226 (18.3) Oesophagus 93 (3.9)
NHL 95 (7.7) Ovary 89 (3.7)
Diffuse large B cell lymphoma 61 (4.9)
Burkitt’s lymphoma 9 (0.7)
Other NHL 25 (2.0)
Lip, oral cavity and pharynx 26 (2.1) Uterus 84 (3.5)
Vulva 22 (1.8) Colon 54 (2.2)
Uterus 17 (1.4) Lip, oral cavity and pharynx 51 (2.1)
Conjunctiva, Eye 17 (1.4) Lung 48 (2.0)
Lung 15 (1.2) Anorectal 39 (1.6)
Oesophagus 14 (1.1) NHL 30 (1.3)
Diffuse large B cell lymphoma 10 (0.4)
Burkitt’s lymphoma 2 (0.1)
Other NHL 18 (0.8)
Numbers (%) are shown.
*non-squamous cell carcinoma.
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prevalence in previous JCCCS publications exempli-
fied by an antenatal HIV prevalence of 10.4% in 1995
which steadily rose to 29.5% in 2004, plateauing around
this level in the years 2004 to 2012 [23].
We found that younger age, higher level of education
and more recent year of interview were associated with
having been tested for HIV both in men and in women.
Older men and women were less likely to have been
tested; this is consistent with a study of age and gender
differences in HIV testing uptake done in South Africa’s
Mpumalanga province [11]. In Mpumalanga the peak
age-group for HIV testing was 20–39 years for both men
and women; older men and women were less likely toget tested and a significant proportion of older people
who did test did so only after medical referral [11]. Black
cancer patients interviewed in more recent years had a
higher odds of prior HIV testing and, similarly, there
was an increase in HIV testing in the Mpumalanga study
from 2002 to 2006 [11]. Greater availability of HIV test-
ing facilities and of antiretroviral treatment could par-
tially explain improved testing coverage in recent years.
As expected, higher level of education was associated
with greater prevalence of prior HIV testing in both
men and women [14,24]. Indeed, the determinants of
HIV testing in black men and women with cancer are
similar to those seen in the general South African popu-
lation [10,11,14,15].
Figure 2 HIV prevalence in male cancer patients (2004 – 2009). Age-specific HIV prevalence in male cancer patients in the present study
compared with age-specific HIV prevalence in black men in South Africa as reported in the 2008 National HIV Prevalence Survey.
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hormonal contraceptives were also more likely to have
been tested for HIV. Younger women who use hormonal
contraception and who have small children would have
attended health facilities where they will have been
offered HIV testing [15]. Routine opt-out antenatal HIV
testing in pregnant women has been part of the preven-
tion of mother-to-child transmission of HIV (PMTCT)
programme since 2001 [25], which probably explains the
higher HIV testing prevalence in women with young
children. This finding underscores the potential of im-
plementation of PITC when patients with cancer and
HIV co-morbidity can be identified thereby allowing for
appropriate treatment and referral for HIV care.
Men and women with KS had a persistently high HIV
prevalence across the age-groups, whereas for cervicalFigure 3 HIV prevalence in female cancer patients (2004 – 2009). Age
compared with age-specific HIV prevalence in black women in South Africacancer the prevalence was highest in young women and
declined steadily with increasing age. This is consistent
with the young age at cervical cancer diagnosis as previ-
ously described in HIV positive women in South Africa
[26], and supports the hypothesis that HIV works as a
cofactor which shortens the pre-invasive stage in cervical
carcinogenesis [26]. The leading cancers in men and
women differed by HIV status, with AIDS-defining
cancers accounting for 59% and 62% of all cancers in
HIV positive men and women respectively. The non-
AIDS defining cancers Hodgkin lymphoma and skin
(non-melanoma, non-squamous cell carcinoma) in
men, and vulval and conjunctival cancers in women
emerged in the top ten. The association of these non-
AIDS defining cancers with HIV has been described be-
fore in the JCCCS [16] and in other African settings-specific HIV prevalence in female cancer patients in the present study
as reported in the 2008 National HIV Prevalence Survey.
Table 3 Factors associated with HIV testing in black South African men with cancer (2004 – 2009)
Factor No previous HIV test
N (%)
Previous HIV test
N (%)
Crude logistic model
OR (95% CI)
Multivariate logistic model
OR (95% CI)
Age
≤49 years 641 (45.8) 238 (60.7) 1 1
>49 years 760 (54.2) 154 (39.3) 0.54 (0.43 – 0.68) 0.49 (0.39 – 0.63)
Place of residence
Urban 1241 (88.6) 367 (93.6) 1 1
Rural 160 (11.4) 25 (6.4) 0.53 (0.34 – 0.82) 0.61 (0.39 – 0.97)
Marital status
Married/living together 960 (68.6) 249 (63.7) 1
Single/never married 170 (12.2) 48 (12.3) 1.09 (0.77 – 1.54)
Widowed 99 (7.1) 36 (9.2) 1.40 (0.93 – 2.10)
Separated/divorced 170 (12.2) 58 (14.8) 1.32 (0.95 – 1.83)
Year of interview
2004-2005 197 (14.1) 30 (7.7) 1 1
2006 235 (16.8) 38 (9.7) 1.06 (0.63 – 1.78) 1.04 (0.61 – 1.76)
2007 351 (25.1) 77 (19.6) 1.44 (0.91 – 2.27) 1.88 (1.17 – 3.02)
2008 355 (25.3) 107 (27.3) 1.98 (1.27 – 3.07) 2.44 (1.54 – 3.85)
2009 263 (18.8) 140 (35.7) 3.49 (2.26 – 5.40) 4.13 (2.62 – 6.52)
Level of education
None 145 (10.4) 24 (6.1) 1 1
Primary 495 (35.4) 94 (24.0) 1.15 (0.71 – 1.86) 1.14 (0.69 – 1.89)
Secondary/tertiary 758 (54.2) 274 (69.9) 2.18 (1.39 – 3.44) 1.79 (1.11 – 2.90)
Alcohol use
Non-drinkers 397 (28.3) 118 (30.1) 1
Moderate drinkers 635 (45.3) 165 (42.1) 0.87 (0.67 – 1.14)
Heavy/binge drinkers 369 (26.3) 109 (27.8) 0.99 (0.74 – 1.34)
Smoking
Non-smokers 318 (22.7) 100 (25.5) 1
Ex-smokers 221 (15.8) 52 (13.3) 0.75 (0.51 – 1.09)
Current smokers (1–14 g/day) 580 (41.4) 155 (39.5) 0.85 (0.64 – 1.13)
Current smokers (15+ g/day) 282 (20.1) 85 (21.7) 0.96 (0.69 – 1.33)
Lifetime number of sexual partners
0-1 89 (6.5) 21 (5.5) 1
2-5 633 (46.3) 156 (41.2) 1.04 (0.63 – 1.73)
6+ 645 (47.2) 202 (53.3) 1.33 (0.80 – 2.19)
Having children under 5 years
No 828 (79.8) 228 (75.2) 1
Yes 210 (20.2) 75 (24.8) 1.30 (0.96 – 1.75)
Cancer type
AIDS-defining 294 (21.0) 104 (26.5) 1
Other cancers 1107 (79.0) 288 (73.5) 0.73(0.57 – 0.95)
Interviewer
Interviewer 1 771 (55.0) 291 (74.2) 1 1
Interviewers 2 and 3 630 (45.0) 101 (25.8) 0.69 (0.63 – 0.76) 0.43 (0.33 – 0.56)
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Table 4 Factors associated with HIV testing in black South African women with cancer
Factor No previous HIV test
N (%)
Previous HIV test
N (%)
Crude logistic model
OR (95% CI)
Multivariate logistic model
OR (95% CI)
Age
≤49 years 1368 (50.1) 707 (77.6) 1 1
>49 years 1364 (49.9) 204 (22.4) 0.29 (0.24 – 0.34) 0.33 (0.27 – 0.41)
Place of residence
Urban 2392 (87.7) 840 (92.3) 1
Rural 336 (12.3) 70 (7.7) 0.59 (0.45 – 0.78)
Marital status
Married/living together 1503 (55.1) 435 (47.9) 1
Single/never married 280 (10.3) 182 (20.0) 2.24 (1.81 – 2.78)
Widowed 483 (17.7) 119 (13.1) 0.85 (0.68 – 1.07)
Separated/divorced 462 (16.9) 173 (19.0) 1.29 (1.05 – 1.59)
Year of interview
2004-2005 497 (18.2) 77 (8.5) 1 1
2006 433 (15.8) 99 (10.9) 1.47 (1.07 – 2.04) 1.61 (1.14 – 2.28)
2007 642 (23.5) 173 (19.0) 1.74 (1.30 – 2.33) 2.91 (2.10 – 4.01)
2008 648 (23.7) 231 (25.4) 2.30 (1.73 – 3.05) 3.62 (2.65 – 4.95)
2009 512 (18.7) 331 (36.3) 4.17 (3.16 – 5.50) 6.04 (4.45 – 8.21)
Level of education
None 336 (12.3) 44 (4.8) 1 1
Primary 880 (32.3) 172 (18.9) 1.49 (1.04 – 2.13) 1.26 (0.86 – 1.84)
Secondary/tertiary 1511 (55.4) 695 (76.3) 3.51 (2.53 – 4.87) 2.08 (1.45 – 2.97)
Alcohol use
Non-drinkers 2071 (75.8) 667 (73.2) 1
Moderate drinkers 401 (14.7) 141 (15.5) 1.09 (0.88 – 1.35)
Heavy/binge drinkers 260 (9.5) 103 (11.3) 1.23 (0.96 – 1.57)
Smoking
Non-smokers 2240 (82.0) 778 (85.4) 1
Ex-smokers 152 (5.6) 32 (3.5) 0.61 (0.41 – 1.90)
Current smokers (1–14 g/day) 278 (10.2) 86 (9.4) 0.89 (0.69 – 1.15)
Current smokers (15+ g/day) 62 (2.3) 15 (1.6) 0.70 (0.39 – 1.23)
Lifetime number of sexual partners
0-1 383 (14.3) 92 (10.3) 1.38 (1.08 – 1.76)
2-5 1962 (73.0) 650 (72.5) 1.87 (1.39 – 2.52)
6+ 342 (12.7) 154 (17.2)
Having children under 5 years 1 1
No 2497 (92.8) 680 (75.5) 4.18 (3.39 – 5.16) 2.59 (2.04 – 3.29)
Yes 194 (7.2) 221 (24.5)
Cancer type
AIDS-defining 1140 (41.7) 385 (42.3) 1
Other 1592 (58.3) 526 (57.7) 0.98 (0.84 – 1.14)
Hormonal contraceptive use
Never 1105 (40.6) 224 (24.7) 1 1
Ever 1615 (59.4) 684 (75.3) 2.09 (1.76 – 2.47) 1.33 (1.09 – 1.62)
Sengayi et al. BMC Cancer  (2015) 15:144 Page 9 of 12
Table 4 Factors associated with HIV testing in black South African women with cancer (Continued)
Interviewer
Interviewer 1 1426 (52.2) 673 (73.9) 1 1
Interviewers 2 and 3 1306 (47.8) 238 (26.1) 0.74 (0.69 – 0.78) 0.36 (0.30 – 0.44)
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defining cancer in HIV positive men in Europe and the
United States [31]. The conspicuous absence of anorectal
cancers in the top ten cancers in HIV positive black men
in our study can be explained by the predominantly het-
erosexual transmission of HIV in South Africa [32]. Con-
junctival cancer was detected among the top ten cancers
in HIV positive female black cancer patients but was not
in the top ten cancers in HIV positive men. This might
reflect differences in health seeking behaviours between
men and women, hindering diagnosis in men. Also, it
might possibly reflect an HIV-related shift from the male
predominance of conjunctival cancer to a female predom-
inance as previously observed in a study of conjunctival
cancer in Zimbabwe, where 70% of conjunctival cancers
were in women [33].
The overall undiagnosed HIV prevalence of 11.5% is
comparable to other studies done in the general popula-
tion; the prevalence of previously undiagnosed HIV was
10.3% in a population-based sero-survey done in Cape
Town [13]. In the current study, over a third of HIV
positive cancer patients were unaware of their HIV
status. This is concerning and has implications for man-
agement of cancer patients. Undiagnosed HIV infection
could potentially worsen treatment outcomes for cancer
patients, who might have untreated HIV-related immu-
nodeficiency in addition to coping with cancer-specific
chemotherapy, radiation therapy or surgery. Further re-
search is required to understand why newly diagnosed
cancer patients are not routinely tested for HIV or are
unaware of their HIV result.
Our analysis has some limitations. In the first 2 years
(November 2004 – November 2006) of introduction of
the HIV section of the questionnaire, it was only used
for patients aged 55 or less; thereafter it was used for all
patients. Patients not interviewed on HIV testing were
therefore older, and had a lower HIV prevalence than
those interviewed (see Additional file 1: Table S5). This
might have inflated overall HIV prevalence in the study.
Furthermore, there was potential for recall bias and dif-
ferential reporting of previous HIV testing in patients
who had and had not previously tested positive for HIV.
Although interviews were conducted by experienced
nurse counsellors there was possible social desirability
bias, as patients might want to give health care workers
responses which cast them favourably. Self-reported HIV
status may overestimate true lack of awareness of HIV sta-
tus where patients who are aware of their HIV positivestatus may report unknown or HIV negative status [34].
Hence HIV stigma might have affected the high preva-
lence of undiagnosed HIV. The study was limited to black
cancer patients who were mainly from southern Gauteng
province; thus the results may not apply to other prov-
inces in South Africa or other countries in sub-Saharan
Africa. This study was conducted during the period 2004–
2009; since then there has been continued ART scale-up,
and in 2010, national HIV testing guidelines were pub-
lished and a national HIV testing campaign was imple-
mented [6,35]. Therefore current HIV testing patterns and
HIV burden in cancer patients might differ from the find-
ings of this study. HIV testing patterns in cancer patients
in South Africa had not previously been studied. The
current analysis provides a baseline picture of HIV testing
patterns in cancer patients in the first five years of the
roll-out of antiretroviral combination therapy in South
Africa. Another strength is the large sample size, which
allowed for precise estimates. The majority of patients had
independent study related HIV test results and most other
variables were fairly complete.
Conclusions
HIV prevalence is higher in black cancer patients in
Johannesburg than in the general black population, even
among patients with cancers which are not AIDS defin-
ing. Clinicians should not miss the opportunity to offer
PITC to cancer patients at the time of cancer diagnosis.
The HIV testing patterns in black cancer patients reflect
targeted HIV testing in the reproductive age group.
More than a third of newly diagnosed black cancer pa-
tients with HIV were unaware of their HIV status. This
emphasises the need for implementation of PITC not only
in the general population, but also in black cancer patients
in South Africa’s high HIV prevalence setting. Routine
opt-out HIV testing in black cancer patients should be
implemented as standard of care in South Africa.
Additional file
Additional file 1: Table S5. Differences in characteristics of patients
interviewed and not interviewed on HIV testing. Table S6. prevalence of
HIV and undiagnosed HIV by cancer type.
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